Appendix

Clinical Trials

An open label, multicenter study, evaluating the safety and imaging characteristics of 18F-AV-1451 in cognitively healthy volunteers, subjects with Mild Cognitive Impairment, and subjects with Alzheimer’s Disease

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer’s Disease

A Clinico-Pathological Study of the Correspondence Between 18F-AV-1451 PET Imaging and Post-Mortem Assessment of Tau Pathology

A Pilot Study: Reducing Post-Operative Delirium and Other Complications Associated with Cognitive Impairment in Orthopedic Surgery

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy And Safety Study Of Crenezumab In Patients With Prodromal To Mild Alzheimer’s Disease

A 15-Week, Phase 2, Double Blind, Randomized, Placebo-Controlled, Dose Ranging Study To Investigate The Efficacy, Safety And Tolerability of PF-06649751 In Subjects With Motor Fluctuations Due To Parkinson’s Disease

An open label, multicenter study evaluating the imaging characteristics of a follow up 18F-AV-1451 scan in subjects that participated in the confirmatory cohort of 18F-AV-1451-A05 (AVID A18)

A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, MulticenterStudy Investigating the Efficacy and Safety of JNJ-54861911 in Subjects who areAsymptomatic At Risk for Developing Alzheimer’s Dementia

A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients with Parkinson’s Disease Experiencing End of Dose “Wearing-Off”

Providence Cognitive Decline Intervention Trial

Thromboaspiration of Downstream and New Territory Emboli Using the 3Max catheter after Mechanical Thrombectomy of Large Vessel Occlusions